GenSci153

GenSci153 is an innovative radiopharmaceutical and radioligand therapy (RLT) being developed by Jinsaixing Medical Technology (GenSci) for the treatment of prostate cancer. As a radioligand therapy, it is designed to deliver a radioactive payload directly to cancer cells by targeting specific molecular markers associated with prostate cancer, thereby inducing targeted cell death while sparing healthy tissue. The drug is currently in the IND-enabling phase of development. According to company milestones, investigator-initiated trials (IIT) are planned to begin in the first half of 2026, with initial data readouts expected in the second half of that year. GenSci153 is positioned as a potential best-in-class therapy within the developer's oncology pipeline.